Compare · IRTC vs RMD
IRTC vs RMD
Side-by-side comparison of iRhythm Holdings Inc. (IRTC) and ResMed Inc. (RMD): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both IRTC and RMD operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- RMD is the larger of the two at $28.44B, about 8.0x IRTC ($3.55B).
- Over the past year, IRTC is down 26.7% and RMD is down 21.9% - RMD leads by 4.7 points.
- IRTC has been more active in the news (17 items in the past 4 weeks vs 6 for RMD).
- Both have 25 recent analyst ratings on file.
- Company
- iRhythm Holdings Inc.
- ResMed Inc.
- Price
- $108.06+0.66%
- $196.01+0.92%
- Market cap
- $3.55B
- $28.44B
- 1M return
- -8.08%
- -6.57%
- 1Y return
- -26.69%
- -21.95%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NYSE
- IPO
- 2016
- News (4w)
- 17
- 6
- Recent ratings
- 25
- 25
iRhythm Holdings Inc.
iRhythm Technologies, Inc., a digital healthcare company, provides ambulatory electrocardiogram (ECG) monitoring products for patients at risk for arrhythmias in the United States. It offers Zio service, an ambulatory cardiac monitoring solution that combines a wire-free, patch-based, and wearable biosensor with a cloud-based data analytic platform to help physicians to monitor patients and diagnose arrhythmias. The company's Zio XT and AT monitors, a single-use, wire-free, and wearable patch-based biosensors, records patient's heartbeats and ECG data. It has a development collaboration agreement with Verily Life Sciences LLC to develop various next-generation atrial fibrillation screening, detection, or monitoring products. iRhythm Technologies, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.
ResMed Inc.
ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications that diagnose, treat, and manage respiratory disorders comprising sleep apnea, chronic obstructive pulmonary disease, neuromuscular disease, and other chronic diseases. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, portable oxygen concentrators, and cloud-based software informatics solutions to manage patient outcomes, as well as provides customer and business processes. The company also provides U-Sleep, which enables automated patient coaching through a text, email, or interactive voice phone call; AirView that enables remote monitoring, over-the-air trouble shooting, and changing of device settings; and myAir, a patient engagement application that offers sleep data and a daily score based on their previous night's data, as well as connectivity module and propeller solutions. In addition, it provides business management software and services to out-of-hospital providers, home medical equipment, pharmacy, home infusion, orthotics, and prosthetics; and HEALTHCAREfirst and MatrixCare solutions. The company markets its products to sleep clinics, home healthcare dealers, patients, hospitals, physicians, and third-party payers through a network of distributors and direct sales force in approximately 140 countries. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.
Latest IRTC
- iRhythm Holdings Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- EVP, Chief Risk Officer Shrishrimal Sumi was granted 133 shares and sold $185,652 worth of shares (1,716 units at $108.19), decreasing direct ownership by 4% to 40,287 units (SEC Form 4) to satisfy tax liability
- Chief Accounting Officer Rosenbaum Marc Wade was granted 178 shares and sold $78,870 worth of shares (729 units at $108.19), decreasing direct ownership by 3% to 16,155 units (SEC Form 4) to cover withholding tax
- CHIEF MED/SCI OFCR EVP ADVTECH Turakhia Minang was granted 137 shares, increasing direct ownership by 0.25% to 55,043 units (SEC Form 4)
- CHIEF COMM & PRODUCT OFFICER Patterson Chad was granted 177 shares, increasing direct ownership by 0.30% to 58,341 units (SEC Form 4)
- EVP, Strategy & Corp Devt Freeman Sean Clinton was granted 273 shares, increasing direct ownership by 2% to 14,559 units (SEC Form 4)
- President and CEO Blackford Quentin S. was granted 178 shares, increasing direct ownership by 0.09% to 204,333 units (SEC Form 4)
- Director Bairey Merz Cathleen Noel was granted 1,573 shares, increasing direct ownership by 18% to 10,546 units (SEC Form 4)
- Director Bodaken Bruce G. was granted 1,573 shares, increasing direct ownership by 12% to 14,211 units (SEC Form 4)
- Director Ling Karen was granted 1,573 shares, increasing direct ownership by 16% to 11,141 units (SEC Form 4)
Latest RMD
- Global General Counsel Rider Michael J covered exercise/tax liability with 269 units of ResMed Common Stock, decreasing direct ownership by 3% to 9,488 units (SEC Form 4) (tax withholding)
- Angelini Ventures Marks First Portfolio Company Exit as ResMed Acquires Noctrix Health for $340 million
- Resmed Completes Acquisition of Noctrix Health, Expanding Clinical Sleep Health Portfolio
- SEC Form SD filed by ResMed Inc.
- Resmed Announces Participation in the 46th Annual William Blair Growth Stock Conference
- Resmed and ŌURA Partner to Expand Access to Sleep Health Education and Care
- Chairman and CEO Farrell Michael J. exercised 4,991 units of ResMed Common Stock at a strike of $146.34 and sold $1,037,233 worth of ResMed Common Stock (4,991 units at $207.82) as part of a pre-agreed trading plan (SEC Form 4)
- SEC Form 3 filed by new insider Bloomer Aaron
- SEC Form 4 filed by Chief Financial Officer Sandercock Brett
- SEC Form 8-K filed by ResMed Inc.